<DOC>
	<DOCNO>NCT02243280</DOCNO>
	<brief_summary>The purpose Phase 2 , open-label , 2-part , multicenter study evaluate efficacy , safety , pharmacokinetics co-administration ABT-493 ABT-530 without ribavirin ( RBV ) different dos chronic Hepatitis C virus ( HCV ) Genotype 1 ( GT1 ) , Genotype 4 ( GT4 ) , Genotype 5 ( GT5 ) , Genotype 6 ( GT6 ) infection compensate cirrhosis ( GT1 ) without cirrhosis ( GT1 , GT4 , GT5 , GT6 ) . Although RBV initially plan protocol , administer study arm .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety , Pharmacokinetics Co-administration ABT-493 ABT-530 With Without Ribavirin Subjects With HCV Genotype 1 , 4 , 5 , 6 Infection</brief_title>
	<detailed_description>This study consist two independent part : Part 1 conduct first follow Part 2 . Part 1 enrolled participant receive ABT-493 ABT-530 12 week ; Part 2 enrol participant receive ABT-493 ABT-530 8 12 week . Participants complete prematurely discontinue treatment period follow 24 week monitor HCV RNA evaluate efficacy emergence persistence viral variant .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>1 . Male female 18 70 year age , inclusive , time screen 2 . Screening laboratory result indicate hepatitis C virus ( HCV ) GT1 ( Study Parts 1 2 ) GT4 , GT5 , GT6 ( Study Part 2 ) infection 3 . Chronic HCV infection define one following : Positive antiHCV antibody ( Ab ) HCV RNA least 6 month screen , positive HCV RNA antiHCV Ab time screen Positive antiHCV Ab HCV RNA time screen liver biopsy consistent chronic HCV infection ( liver biopsy perform prior enrollment evidence chronic HCV infection ) 4 . Participant meet one follow criterion : Treatmentnaïve : participant never receive treatment HCV infection Treatmentexperienced : pegylatedinterferon alpha2a alpha2b ribavirin ( PR ) null responder ( Study Part 1 ) PRexperienced ( ontreatment failure prior relapse ) ( Study Part 2 ) 5 . Documented absence cirrhosis ( Study Part 1 correspond arm Study Part 2 ) , compensate cirrhosis ( correspond arm Study Part 2 , GT1 ) , per local standard 1 . History severe , lifethreatening significant sensitivity drug 2 . Female pregnant , plan become pregnant study breastfeeding ; male whose partner pregnant planning become pregnant study 3 . Recent ( within 6 month prior study drug administration ) history drug alcohol abuse could preclude adherence protocol opinion investigator 4 . Positive test result Screening hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( HIV Ab ) 5 . Hepatitis C virus ( HCV ) genotype perform screen indicate coinfection one HCV genotype 6 . Any cause liver disease chronic HCV infection 7 . Participants plasma HCV RNA load ≤ 10,000 international unit ( IU ) /mL unquantifiable undetectable HCV RNA screen 8 . Previous use HCV directacting antiviral agent ( DAA ) 9 . Consideration investigator , reason , participant unsuitable candidate receive ABT493 , ABT530 , RBV ( RBV cirrhotic subject ) 10 . For participant Study Part 2 enrol compensate cirrhosis : past clinical evidence ChildPugh B C Classification ( score &gt; 6 ) clinical history liver decompensation , include ascites ( noted physical exam ) , bleed varix , use betablockers portal hypertension ascites , hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HCV GT4</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HCV GT1</keyword>
	<keyword>HCV</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>HCV GT6</keyword>
	<keyword>Hepatitis C Genotype 4 ( GT 4 )</keyword>
	<keyword>Hepatitis C Genotype 1 ( GT1 )</keyword>
	<keyword>RBV</keyword>
	<keyword>Cirrhotic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon ( IFN ) Free</keyword>
	<keyword>IFN free</keyword>
	<keyword>HCV GT5</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Child Pugh A</keyword>
	<keyword>Hepatitis C Genotype 5 ( GT 5 )</keyword>
	<keyword>Hepatitis C Genotype 6 ( GT 6 )</keyword>
	<keyword>ABT-493</keyword>
	<keyword>ABT-530</keyword>
	<keyword>glecaprevir</keyword>
	<keyword>pibrentasvir</keyword>
</DOC>